---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-034814"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2022-12-08T23:59:59+00:00"
generated_at: "2026-06-21T07:26:02.464774+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bioxytran receives CDSCO approval for Phase 1b/2a trial of ProLectin-M in COVID-19 patients

## Summary
- IND authorization from India's CDSCO for a Phase 1b/2a randomized, blinded, placebo-controlled study of ProLectin-M in mild-to-moderate COVID-19.
- Trial will evaluate safety, efficacy, and pharmacokinetics of oral ProLectin-M; results to guide a 408-patient Phase III trial.
- Condition: each site must obtain Ethics Committee approval before starting enrollment.
- Press release issued December 8, 2022.

## SEC filing metadata
- accession: 0001493152-22-034814
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2022-12-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315222034814/0001493152-22-034814-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315222034814/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-034814
- JSON: https://secwatch.observer/filing/0001493152-22-034814.json
- Plain text: https://secwatch.observer/filing/0001493152-22-034814.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.